S

Spectrum Clinical Research | Maryland Cardiovascular Specialists

Research site
(Unclaimed)
Location
3407 Wilkens Avenue, Suite 300, Baltimore, Maryland, United States of America

Site insights

Top conditions

Top treatments

Tirzepatide
LY3298176
Olezarsen
Bococizumab
Orforglipron
Linagliptin
Glucose
K-877
Evolocumab
Pemafibrate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 27 total trials
Locations recently updated

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Active, not recruiting
Hypertriglyceridemia
Cardiovascular Diseases
Drug: Placebo
Drug: Olezarsen

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from ba...

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen
Drug: Placebo

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejec...

Active, not recruiting
Heart Failure With Preserved Ejection Fraction (HFpEF)
Obesity
Other: Placebo
Drug: Tirzepatide

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and...

Enrolling
Dyslipidemias
Hypercholesterolemia
Other: Combination Therapy placebo
Other: Ezetimibe Placebo

The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiov...

Active, not recruiting
Heart Failure
Other: Placebo
Drug: Finerenone (BAY94-8862)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Overweight and Obesity
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Lilly logo
Amgen logo
Pfizer logo
Bayer logo
Boehringer Ingelheim logo
Ionis Pharmaceuticals logo
Kowa logo
AbbVie logo
A
Eisai logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems